Increased Neointimal Thickening in Dystrophin-Deficient mdx Mice by Rauch, Uwe et al.
Increased Neointimal Thickening in Dystrophin-Deficient
mdx Mice
Uwe Rauch, Annelie Shami, Feng Zhang, Virginie Carmignac, Madeleine Durbeej*, Anna Hultga ˚rdh-
Nilsson
Department of Experimental Medical Science, Lund University, Lund, Sweden
Abstract
Background: The dystrophin gene, which is mutated in Duchenne muscular dystrophy (DMD), encodes a large cytoskeletal
protein present in muscle fibers. While dystrophin in skeletal muscle has been extensively studied, the function of
dystrophin in vascular smooth muscle is less clear. Here, we have analyzed the role of dystrophin in injury-induced arterial
neointima formation.
Methodology/Principal Findings: We detected a down-regulation of dystrophin, dystroglycan and b-sarcoglycan mRNA
expression when vascular smooth muscle cells de-differentiate in vitro. To further mimic development of intimal lesions, we
performed a collar-induced injury of the carotid artery in the mdx mouse, a model for DMD. As compared with control mice,
mdx mice develop larger lesions with increased numbers of proliferating cells. In vitro experiments demonstrate increased
migration of vascular smooth muscle cells from mdx mice whereas the rate of proliferation was similar in cells isolated from
wild-type and mdx mice.
Conclusions/Significance: These results show that dystrophin deficiency stimulates neointima formation and suggest that
expression of dystrophin in vascular smooth muscle cells may protect the artery wall against injury-induced intimal
thickening.
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Introduction
Duchenne muscular dystrophy (DMD) is a severe form of
muscular dystrophy with X-linked recessive inheritance, caused by
mutations in the gene encoding dystrophin [1]. DMD is
characterized by progressive muscle wasting with a clinical onset
at 2–5 years of age, ambulatory loss between ages 7 to 13 and
death at 20–30 years of age due to cardiopulmonary failure [2].
The mdx (X-chromosome-linked muscular dystrophy) mouse is
considered as the best animal model for DMD. Due to a point
mutation in exon 23, mdx mice are missing dystrophin.
Consequently, mdx mice develop muscular dystrophy, although
the progressive muscle wasting presents itself in a much milder
form than in humans, at least in the majority of the skeletal
muscles. One notable exception is the mdx diaphragm, which
reproduces the degenerative changes of muscular dystrophy. Yet,
mdx mice have only a slightly shorter life-span compared to wild-
type mice [3].
Dystrophin is a large intracellular protein that is localized to the
sarcolemma through interactions with a large complex of
membrane-associated and other cytosolic proteins, composed of
dystroglycans (a, b), sarcoglycans (a, b, c, d), sarcospan and the
syntrophins [4–6]. This dystrophin-glycoprotein complex (DGC)
connects the subsarcolemmal cytoskeleton of a skeletal muscle
fiber to its surrounding extracellular matrix and is believed to
protect the skeletal muscle fiber from contraction-induced damage
[7–9]. Dystrophin and the other components of the DGC are not
only expressed in skeletal and cardiac muscle cells but also in
vascular and other types of smooth muscle cells as well as in
endothelial cells [10–15]. However, the functional role of
dystrophin in vasculature is less clear. The presence of dystrophin
in vascular smooth muscle appears to influence the nNOS-
mediated attenuation of norepinephrine-mediated vasoconstric-
tion that occurs in contracting muscles [16]. Moreover, carotid
and mesenteric arteries from the mdx mouse model of dystrophin
deficiency do not dilate properly under shear stress [12,17]. Also,
biomechanical properties of carotid arteries are altered in the mdx
mice [17]. Finally, complete loss of the vascular smooth muscle
DGC could contribute to the development of vascular spasm in
sarcoglycan-deficient cardiomyopathy [18,19] although more
recent data suggest that cytokine release from degenerating
cardiac myocytes may produce vascular spasm [20].
Vascular smooth muscle cells can undergo rapid and reversible
phenotypic changes in response to stress and vascular injury. A
differentiated vascular smooth muscle cell phenotype is charac-
terized by expression of specific contractile and cytoskeletal
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pressure and flow [21,22]. The other important function of the
vascular smooth muscle cell is the repair mechanism, which is
activated as a response to vascular injury. The smooth muscle cells
then lose their contractility, start to proliferate and migrate into
the innermost layer (intima) of the vessel, where they synthesize
and deposit vast amounts of extracellular matrix (ECM) molecules
[21,22]. Such phenotypic modulation also takes place during the
first week when primary smooth muscle cells are grown in culture
[23,24]. The vascular smooth muscle cell plays an important role
both during the development of atherosclerotic plaques and in the
formation of restenotic lesions. In the latter situation, endovascular
procedures have an important limitation due to ECM production
and aggressive smooth muscle cell proliferation, and much of
current research is devoted to the prevention of these activities, for
example by inhibition of smooth muscle cell matrix receptor
interactions [25].
Here, we have analyzed the role of dystrophin in neointima
formation as a response to vessel wall injury. For this purpose, we
used a carotid periadventitial collar injury model. We found
increased neointima formation in dystrophin-deficient mdx animals
compared to control animals.
Materials and Methods
Animals
Mdx (C57BL/10ScSn-mdx/J) and control mice were obtained
from Jackson Laboratory. All mouse experimentation was
approved by the Malmo ¨/Lund (Sweden) Ethical Committee for
Animal Research (permit number M62-10). All mice were
maintained in animal facilities according to animal care guidelines.
Cell culture
Vascular smooth muscle cells from control and mdx mice (n=6
of each) were isolated from aortas, which had been stripped of
endothelial cells through scraping with a cotton swab. The tissue
was digested in 0.3% collagenase (type II, Gibco) in Ham’s F-12
medium (Gibco) supplemented with 50 mg/ml gentamicin, 5 mg/
ml ascorbic acid (Sigma) and 1% bovine serum albumin and the
cells were immediately seeded in plastic cell culture plates to be
incubated at 37uC (5% CO2) in Ham’s F-12 medium (Gibco)
supplemented with 50 mg/ml gentamicin, 5 mg/ml ascorbic acid
(Sigma) and 10% newborn calf serum (Gibco). In vitro proliferation
assay was performed with the 5-Bromo-29-deoxy-uridine (BrdU)
Labelling and Detection Kit III (Roche). Vascular smooth muscle
cells isolated from control and mdx mice were seeded (3500 per
well in a minimum of 12 wells per parameter) in 96 well plates in
F-12 medium containing 10% NCS (Gibco). BrdU labelling
solution was added 6 hours after seeding. Cells were then
incubated for 44 hours before quantification of incorporated
BrdU was completed according to the manufacturer’s instructions.
For the in vitro transwell migration assay smooth muscle cells were
seeded in the upper chamber of 8 micron transwells (Corning). F-
12 medium in the upper chamber contained 1% bovine serum
albumin (Sigma) and F-12 medium containing 10% NCS was
added to the lower chamber. Cells were allowed to migrate for
20 hours. The filter was then cut from the chamber insert and cells
that had migrated were counted (in area of 6 mm
2 in the centre of
the filter).
RNA extraction, reverse transcription and quantitative
real-time PCR
Total RNA was extracted from freshly isolated (contractile) or
cultured (5–7 days; synthetic) smooth muscle cells from 6 and 8
wild type mice, respectively, using RNeasy mini kit (Qiagen).
Complementary DNA was synthesized from l mg of total RNA
with random primers and SuperScriptIII reverse transcriptase
(Invitrogen) following manufacturer’s instructions. Quantitative
PCRs were performed in triplicate with the Maxima SYBR Green
qPCR Master Mix (Fermentas). Expression of target and reference
genes was monitored using a quantitative real-time RT-PCR
method (Light Cycler, Roche) with primers for dystrophin (forward:
59-AGCACAGGGCTATGAACAAAC-39; reverse: 59-ACTTC-
CGTCTCCATCAATGAAC-39), dystroglycan (forward: 59-AGA-
AAGTGGTAGAGAATGGGG-39; reverse 59-AGTAACAGGT-
GTAGGTGTGG-39) and b-sarcoglycan (forward: 59-AGCATG-
GAGTTCCACGAGAG-39; reverse: 59-GCTGGTGATGGAG-
GTCTTGT-39) genes. Primers were designed using Primer3-Web
(v. 0.4.0) (http://frodo.wi.mit.edu/primer3/input.htm). The am-
plification efficiency for each primer pair was evaluated by
amplification of serially diluted template cDNAs (E=10
-r/slope).
Efficiency corrected RNA levels (in arbitrary units) were calculated
by using the formula E
-Ct. Expression levels were then calculated
relative to the endogenous control gene GAPDH.
Periadventitial collar injury
At the age of approximately 4–5 months, mice (n=11 for mdx
and n=6 for wild-type) were anesthetized with Ketamine
(110 mg/kg)/Rompun (10–13 mg/kg) and the right carotid artery
was carefully isolated under a dissecting microscope. A non-
occlusive plastic collar was placed around the right carotid artery
and the skin incision was closed, as described previously [26,27].
Mice were sacrificed 21 days after collar placement and the carotid
arteries were perfusion-fixed with Histochoice (Amresco), dissected
out and stored in Histochoice at 4uC until paraffin embedded.
Morphometric measurements
The carotid arteries were sectioned (5 mm) and one section
every 100 mm was used for measurements of the atherosclerotic
extent (approximately 10–20 sections per animal). Accustain
elastic stain kit (Sigma) was used to visualize elastic laminae and
areas of the different regions and circumferences were calculated
using the Zeiss Axiovision image software (Zeiss). Lumen and
medial (the area between the external elastic laminae and internal
elastic laminae) areas were calculated. Lesion area was calculated
by subtracting the lumen area from the internal elastic laminiae
area.
Immunohistochemistry
PCNA stainings of paraffin sections were performed using the
PCNA staining kit from Invitrogen according to the manufactur-
er’s instruction with the addition of quenching of endogenous
peroxidase activity as well as heat induced antigen epitope
retrieval (pH 6.0 for 20 minutes).
Fluorescence immunohistochemistry
Aortas stored at 4uC were removed from Histochoice and
cryoprotected in 30% sucrose phosphate buffer, embedded in
OCT (Tissue-Tek OCT, Sakura Japan) compound for sectioning
and frozen in isopentan/dry ice. Frozen tissue specimens were cut
with a Microm HM 560 microtome into 6 mm sections and air
dried on Superfrost plus slides (Menzel, Germany) for 30 minutes
and stored at 280uC for further use. For immunofluorescence
detection of antigens, frozen slides were left to dry at room
temperature and submerged for 10 minutes in 220uC methanol,
transferred to PBS and blocked with 5% goat serum in PBS for
1 hour at room temperature except stainings for smooth muscle a-
Role of Dystrophin in Neointima Formation
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e29904actin and b-sarcoglycan, which were blocked with MOM-block,
further processed following the basic protocol of the MOM-kit
(Vector labs), and visualized with Cy3-streptavidin (Sigma). For
laminin a2 chain, PCNA, and b-dystroglycan stainings the goat
serum blocking solution was exchanged against antibodies diluted
in blocking solution overnight. Slides were washed with PBS and
incubated with Cy3-linked secondary antibody (goat anti rabbit Ig,
Jackson) in PBS for 1 hour at room temperature, washed again
and mounted with Vectashield (Vector labs). For the CD68
staining (performed together with PCNA) FITC- linked secondary
antibodies (goat anti rat Ig, Jackson) were used. Images were taken
on a Zeiss Axiophot 2 with a Hamamatsu C4742-95 camera and
Openlab 5 software (Improvision). Antibodies against laminin a2
chain [28] were kindly provided by Dr. Lydia Sorokin, Muenster.
Antibodies against b-dystroglycan were described previously [29];
smooth muscle a-actin antibodies (clone 1A4) were from Sigma;
anti-b-sarcoglycan antibodies (clone bSarc/5B1) from Novocastra;
anti-CD68 antibodies (clone FA-11) from AbD Serotec and anti-
PCNA antiserum from Abcam (ab15497).
Statistics
Results are expressed as mean 6 SEM. For mRNA analyses,
Student t-test was performed for analysis of significance and for
the other measurements, the statistical significance between groups
was determined by Mann-Whitney test (using GraphPad Prism
version 4.0). P,0.05 was considered significant.
Results
In response to vascular injury, medial smooth muscle cells lose
their contractility and they migrate into the innermost layer of the
vessel, where they start to proliferate and secrete ECM molecules.
To investigate if dystrophin is altered when vascular smooth
muscle cells undergo a phenotypic modulation from contractile to
non-contractile synthetic cells, we used a well-established tech-
nique of culturing isolated mouse aortic vascular smooth muscle
cells [23,24]. Directly after collagenase digestion, when the smooth
muscle cells are in a contractile phenotype, they strongly expressed
dystrophin mRNA. After 5–7 days in culture, the cells had
changed into a synthetic phenotype and at this time point the
expression of dystrophin mRNA was shown to be dramatically
decreased (Fig. 1). The reduction in dystrophin expression was
accompanied by a significant reduction of dystroglycan and b-
sarcoglycan mRNA expression (Fig. 1).
To study the role of dystrophin in neointima formation in vivo,
we performed collar injury on carotid arteries in mdx and control
mice. This type of vessel wall injury generates a lesion rich in
smooth muscle cells and ECM, which is similar to human
restenotic lesions [26,30]. Histopathological examination of
carotid artery cross section 21 days after injury revealed markedly
enhanced neointimal thickening in mdx mice (Fig. 2B) compared
with wild-type mice (Fig. 2A). To quantify the changes in vessel
wall geometry, we measured the intimal and medial areas of mdx
and control mice. In mdx mice, collar injury of the carotid artery
caused a significant increase in neointimal area compared to wild-
type animals (23 55763409 units versus 11 77161997 units,
respectively, p,0.05, Fig. 2C), whereas there was no significant
difference in the medial area between mdx and wild-type mice (36
19361781 units versus 35 16961393 units, respectively, p=NS,
Fig. 2C). Hence, intima/media ratio remained significantly
increased in mdx as compared with control mice (0.3360.05
versus 0.6560.09, p,0.05, Fig. 2C).
We also assessed the rate of proliferation of vascular smooth
muscle cells in the media and neointima using an antibody against
the proliferative marker PCNA. The mean number of PCNA-
positive cells was approximately 2-fold higher in the neointimal
lesions of mdx mice than those of wild-type mice (16.962.9%
versus 6.060.9%, respectively, p=0.0013, Fig. 3A–C), whereas
there was no significant difference between the two groups
regarding the number of PCNA-positive cells in the media (data
not shown). It is well documented that a majority of the cells in a
mechanically induced arterial lesion at a late time point of 21 days
are vascular smooth muscle cells [31]. To further demonstrate that
most PCNA-positive cells were vascular smooth muscle cells,
rather than inflammatory cells, we performed double immunoflu-
orescence staining using antibodies against PCNA and the
macrophage/leukocyte marker CD68. Indeed, CD68-positive
cells were typically localized in the media and adventitia, whereas
PCNA-positive cells were located in the neointima of injured
arteries from wild-type and mdx mice (Fig. S1). A few CD68-
positive cells, which also were positive for PCNA, were found in
the neointima of injured arteries from mdx mice. Nevertheless, a
majority of the PCNA-positive cells are likely to be vascular
smooth muscle cells.
We next evaluated proliferation as well as migration of vascular
smooth muscle cells in vitro. We could not detect any difference the
rate of proliferation between vascular smooth muscle cells isolated
from wild-type and mdx mice (Fig. 3D) which may be a
consequence of the rapid down regulation of dystrophin mRNA
in cultured wild-type vascular smooth muscle cells (Fig. 1).
However, the serum-induced migration was shown to be increased
with around 20% (476 cells/6 mm
2623 versus 396615 cells/
6m m
2,p ,0.01) in vascular smooth muscle cells from mdx mice
(Fig. 3E). In line with these findings, differential responses of
smooth muscle cells with respect to proliferation and migration in
vitro have been observed previously [32–34]. In addition,
permanent adaptive molecular changes during development of
mdx smooth muscle to compensate for the lack of dystrophin may
enable the cells to migrate, but not proliferate more efficiently in
Figure 1. Reduction of dystrophin, dystroglycan and b-
sarcoglycan mRNAs in synthetic smooth muscle cells. Relative
amounts of dystrophin, dystroglycan and b-sarcoglycan mRNAs in
contractile and synthetic smooth muscle cells (n=6 and 8, respectively).
The GAPDH gene expression served as a reference. ***, p,0.0001.
doi:10.1371/journal.pone.0029904.g001
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in vivo defects are due to loss of dystrophin expression in other cell
types (e.g. endothelial cells) rather than loss of dystrophin in
vascular smooth muscle cells.
Dystrophin is anchored to the sarcolemma through interactions
with dystroglycan, which in turn binds to laminin a2 chain, the
major laminin a chain in the basement membrane covering
skeletal muscle. Also, sarcoglycans are tightly associated with
dystroglycan [35,36]. To determine whether expression of
dystroglycan, laminin a2 chain and b-sarcoglycan is altered
during neointima formation, we performed immunofluorescent
analyses. The appearance of laminin a2 chain between the elastin
layers within the media, demonstrating the presence of a basement
membrane like structures around each individual smooth muscle
cell [37,38], was similar in uninjured carotid vessels of wild-type
and mdx mice (Fig. 4). In these uninjured vessels it coincided with
smooth muscle a-actin, which was present within the cells also
located between the elastic layers of the media (Fig. 4). b-
dystroglycan was evenly and consistently observed in the media of
wild-type mice but less consistently observed in the media of mdx
mice (Fig. 4). b-sarcoglycan, on the other hand, was expressed in
the media of both uninjured wild-type and mdx vessels (Fig. S2).
In both wild-type and mdx mice, laminin a2 staining was present
in the media of injured arteries. In addition, in wild-type mice
laminin a2 chain was also lining the luminal border of the
neointima, as observed previously [38], while in mdx mice laminin
a2 chain was observed throughout the neointima (Fig. 4). In
injured vessels, b-dystroglycan was generally only weakly and
inconsistently observed in the media and neointima of both wild-
type and mdx mice (Fig. 4). In injured arteries, smooth muscle a-
actin was mostly observed in the neointima (Fig. 4). Finally, a
weaker b-sarcoglycan staining was observed in injured wild-type
and mdx arteries (Fig. S2).
Discussion
This is the first study to evaluate the role of dystrophin in
neointima formation as a response to mechanical injury.
Dystrophin is absent in DMD or reduced or truncated in the
milder variant Becker muscular dystrophy. These two disorders
are characterized by skeletal muscle weakness and cardiomyop-
athy [2]. We found that neointima formation after collar-injury is
increased in dystrophin-deficient animals. Hence, it could be that
patients with dystrophin deficiency may more easily develop
atherosclerotic lesions as well as restenotic lesions as a response to
angioplasty. While atherosclerosis may not be a concern for
juvenile DMD males it should perhaps be taken into account for
the clinical care of older DMD men. Nevertheless, it is yet to be
determined whether DMD patients are more susceptible to
development of atherosclerotic and restenotic lesions.
Like it has already been pointed out, upon activation, the
vascular smooth muscle cells lose their contractility, and migrate
from the media into the intima, where they synthesize and deposit
large amounts of ECM proteins. This makes the smooth muscle
Figure 2. Increased neointima formation after vascular injury in mdx mice. Shown are representative sections of wild-type (A) and mdx (B)
mice carotid arteries retrieved 3 weeks post injury and stained for elastin. Bar=100 mm. Intimal (plaque) and medial area and intima/media ratio (C)
was determined 21 days after vascular injury in wild-type (n=6) and mdx (n=10) mice. Data are expressed in thousands of units (kU) of covered area.
*, p,0.05.
doi:10.1371/journal.pone.0029904.g002
Role of Dystrophin in Neointima Formation
PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e29904cell an important player for the fate of both the primary
atherosclerotic lesion as well as for a restenotic lesion. In the
primary lesion, the smooth muscle cells direct the formation and
quality of the fibrous cap covering the atherosclerotic tissue and
protect it from being exposed to the blood [39]. Rupture of a weak
fibrous cap induces a rapid thrombus formation with subsequent
myocardial infarction and stroke. On the other hand, the repair
process by the smooth muscle cell as a response to endovascular
procedure may become uncontrolled, leading to massive prolifer-
ation and matrix production, a situation that may result in
formation of restenotic lesions [30].
In uninjured carotid vessels the individual smooth muscle cells
within the media are individually encased by basement membrane
like structures containing laminin a2 chain [37,38]. While in wild-
type animals the actin cytoskeleton can be linked to the basement
membrane via the DGC and alternatively via integrins, only the
latter interaction may be functional in mdx mice. After injury, a co-
distribution of smooth muscle a-actin and laminin a2 chain
staining is no longer evident, since activated cells leave their native
environment and migrate into the neointima, where they can
switch their integrin receptor repertoire to other subtypes binding
fibronectin, collagen, and other laminin chains. The reduction of
dystroglycan staining indicates that cytoskeletal ECM interactions
mediated by the DGC become less important or are even
inhibitory for this process.
Interestingly, perlecan, a basement membrane resident heparan
sulfate proteoglycan, which binds via its core protein in a similar
way as laminin a2 chain to the dystroglycan complex, has been
implicated in the atherosclerosis process, since it is reduced in
human carotid atherosclerotic lesions [40]. Here, it is concentrated
in a similar way as laminin a2 chain along the luminal border [40].
This leaves smooth muscle cells located within the inner neointima
without apparent extracellular ligand for the DGC. Furthermore,
these observations and our in vitro data are in accordance with the
results from Quignard et al. demonstrating lack of dystrophin in
neointimal cells two weeks after mechanical injury. [41]. Notably,
transgenic mice with a targeted deletion of the major attachment
sites for glycosaminoglycan chains in the perlecan core protein,
which is unlikely to interfere with its ability to bind dystroglycan,
display similar to mdx mice upon mechanical injury increased
intimal hyperplasia and smooth muscle cell proliferation [40].
Hence, it is likely that dystrophin, just like perlecan, plays an
important role in the restenotic process. It will now be interesting
to determine whether dystroglycan, connecting these two
Figure 3. Assessment of cell proliferation in intima after vascular injury in mdx mice. The number of PCNA positive cells per total number
of cells in intima (A) was determined 21 days after vascular injury in wild-type (n=6) and mdx (n=10) mice. **, p,0.01. Also shown are representative
immunohistochemical sections of wild-type (B) and mdx (C) mice carotid arteries retrieved 3 weeks post injury and stained for PCNA. Bar=32 mm. D
and E present the results of in vitro studies with smooth muscle cells isolated from wild-type and mdx mice. D: Rate of BrdU incorporation during 2
days in culture determined by measurement of the absorbance of peroxidase-modified ABTS substrate (AUs: absorbance units). E: Number of cells,
which migrated towards serum-containing medium, observed per 6 mm
2 of the filter bottom.
doi:10.1371/journal.pone.0029904.g003
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vessel wall injury and whether the DGC plays a role in the
development of atherosclerotic lesions.
Supporting Information
Figure S1 Immunofluorescence staining of PCNA and
CD68 positive macrophages in injured carotid arteries.
Sections of carotid lesions from wild-type (A, B, C) and mdx (D, E,
F) mice were stained for PCNA (A and D) and CD68 (B and E).
Images from these staining were merged in C and F showing that
PCNA-positive cells were located in the neointima where few
CD68-positive cells were found. Bar=50 mm. The elastic laminae
are shown by autofluorescence in the green channel.
(TIFF)
Figure S2 Immunohistochemical staining of b-sarcogly-
can in uninjured and injured carotid arteries. Carotid
arteries of uninjured wild-type (A, E) and mdx (B, F) mice and of
injured wild-type (C, G) and mdx (D, H) were stained with a
Figure 4. Immunohistochemical staining of laminin a2 chain, b-dystroglycan, and smooth muscle a-actin in uninjured and injured
carotid arteries. Carotid arteries of uninjured wild-type (A–C) and mdx (D–F) mice and of injured wild-type (G–I) and mdx (J–L) were stained with
anti-sera against laminin a2 chain (A, D, G, J) and b-dystroglycan (B, E, H, K) and an antibody against smooth muscle a-actin (C, F, I, L).
Autofluorescence of the tissue detected in the green channel, in particular of the elastin layers of the media, is presented in green. Note, that the
arrow (in G) is pointing out the luminal border of the plaque, while the arrowhead (in K) is pointing out a b-dystroglycan positive peripheral nerve.
Size bars represent 100 mm for A-F, I & L and 50 mm for G, H, J & K.
doi:10.1371/journal.pone.0029904.g004
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PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e29904primary antibody against b-sarcoglycan (A–D) or without (E–H,
control for anti-mouse IgG) (in red). Autofluorescence, in
particular of the elastin layers of the media, is presented in green.
Note the background staining of the secondary anti-mouse IgGs in
the control of the injured, but not uninjured media. Bar=100 mm.
(TIFF)
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